Zhao Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhao Zhan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Fulan Yang
Department of Breast Surgery Ganzhou People's Hospital 341000 Ganzhou People's Republic of China
1 shared publicationMei Yang
The First School of Clinical Medicine Gannan Medical University 341000 Ganzhou People's Republic of China
1 shared publicationPuwen Chen
The First School of Clinical Medicine Gannan Medical University 341000 Ganzhou People's Republic of China
1 shared publication- Xiaoling Wang
Department of Laboratory Medicine, the First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People’s Republic of China
1 shared publication Yuxin Deng
Center for Clinical Laboratories The Affiliated Hospital of Guizhou Medical University 550001 Guiyang People's Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 14375-14391
Mesenchymal Stem Cell-Derived Extracellular Vesicles in Alzheimer’s Disease: A Novel Cell-Free Therapeutic Strategy and Diagnostic Biomarker
With the ongoing trend of population aging worldwide, the incidence of Alzheimer's disease (AD) is steadily increasing. In the absence of effective therapeutic options for atypical forms of AD, reducing its prevalence and improving treatment outcomes have become pressing priorities. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have attracted growing attention as a new cell-free therapeutic approach for AD due to their high stability, low immunogenicity, and minimal tumorigenic risk. This review provides a comprehensive overview of the pathological mechanisms underlying AD, highlights the diagnostic potential of MSC-EVs, and elaborates on their therapeutic advantages and mechanisms of action. Furthermore, it addresses the key challenges and considerations associated with the clinical translation of MSC-EVs.
- 1 December 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 14375-14391
Open AccessMesenchymal Stem Cell-Derived Extracellular Vesicles in Alzheimer’s Disease: A Novel Cell-Free Therapeutic Strategy and Diagnostic Biomarker
With the ongoing trend of population aging worldwide, the incidence of Alzheimer's disease (AD) is steadily increasing. In the absence of effective therapeutic options for atypical forms of AD, reducing its prevalence and improving treatment outcomes have become pressing priorities. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have attracted growing attention as a new cell-free therapeutic approach for AD due to their high stability, low immunogenicity, and minimal tumorigenic risk. This review provides a comprehensive overview of the pathological mechanisms underlying AD, highlights the diagnostic potential of MSC-EVs, and elaborates on their therapeutic advantages and mechanisms of action. Furthermore, it addresses the key challenges and considerations associated with the clinical translation of MSC-EVs.